Tachikawa Rino, Saito Hiroki, Moteki Hajime, Kimura Mitsutoshi, Kitagishi Hiroaki, Arce Florencio, See Gerard Lee, Tanikawa Takashi, Inoue Yutaka
Laboratory of Nutri-Pharmacotherapeutics Management, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, Sakado, Saitama 3500295, Japan.
Laboratory of Clinical Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, Sakado, Saitama 3500295, Japan.
ACS Omega. 2022 Aug 24;7(35):31233-31245. doi: 10.1021/acsomega.2c03489. eCollection 2022 Sep 6.
The present study prepared inclusion complexes of -allylcysteine (SAC) and cyclodextrin (α, β, γ) by the freeze-drying (FD) method and verified the inclusion behavior of the solid dispersion. Also, the study investigated the effect of SAC/CD complex formation on liver tumor cells. Isothermal titration calorimetry (ITC) measurements confirmed the exothermic titration curve for SAC/αCD, suggesting a molar ratio of SAC/αCD = 1/1, but no exothermic/endothermic reaction was obtained for the SAC/βCD and SAC/γCD system. Powder X-ray diffraction (PXRD) results showed that the characteristic diffraction peaks of SAC and CDs disappeared in FD (SAC/αCD) and FD (SAC/γCD), indicated by a halo pattern. On the other hand, diffraction peaks originating from SAC and βCDs were observed in FD (SAC/βCD). Near-infrared (NIR) absorption spectroscopy results showed that CH and OH groups derived from SAC and OH groups derived from αCD and γCD cavity were shifted, suggesting complex formation due to intermolecular interactions occurring in SAC/αCD and SAC/γCD. Stability test results showed that the stability was maintained with FD (SAC/αCD) over FD (SAC/βCD) and FD (SAC/γCD). In H-H of NOESY NMR measurement, FD (SAC/αCD) was confirmed to have a cross peak at the CH group of the alkene of SAC and the proton (H-3, -5, -6) in the αCD cavity. In FD (SAC/γCD), a cross peak was confirmed at the alkyl group on the carbonyl group side of SAC and the proton (H-3) in the cavity of γCD. From the above, it was suggested that the inclusion mode of SAC is different on FD (SAC/CDs). The results of the hepatocyte proliferation inhibition test using HepG2 cells showed that FD (SAC/βCD) inhibited cell proliferation. On the other hand, FD (SAC/αCD) and FD (SAC/γCD) did not show a significant decrease in the number of viable cells. These results suggest that the difference in the inclusion mode may contribute to the stability and cell proliferation inhibition.
本研究采用冷冻干燥(FD)法制备了S-烯丙基半胱氨酸(SAC)与环糊精(α、β、γ)的包合物,并验证了固体分散体的包合行为。此外,该研究还考察了SAC/CD复合物形成对肝癌细胞的影响。等温滴定量热法(ITC)测量证实了SAC/αCD的放热滴定曲线,表明SAC/αCD的摩尔比为1/1,但SAC/βCD和SAC/γCD体系未获得放热/吸热反应。粉末X射线衍射(PXRD)结果显示,在FD(SAC/αCD)和FD(SAC/γCD)中,SAC和CD的特征衍射峰消失,呈现出晕圈图案。另一方面,在FD(SAC/βCD)中观察到源自SAC和βCD的衍射峰。近红外(NIR)吸收光谱结果表明,源自SAC的CH和OH基团以及源自αCD和γCD空腔的OH基团发生了位移,表明在SAC/αCD和SAC/γCD中由于分子间相互作用形成了复合物。稳定性测试结果表明,FD(SAC/αCD)比FD(SAC/βCD)和FD(SAC/γCD)保持了更高的稳定性。在NOESY NMR测量的H-H中,证实FD(SAC/αCD)在SAC烯烃的CH基团与αCD空腔中的质子(H-3、-5、-6)处有一个交叉峰。在FD(SAC/γCD)中,在SAC羰基侧的烷基与γCD空腔中的质子(H-3)处证实有一个交叉峰。综上所述,提示SAC在FD(SAC/CDs)上的包合模式不同。使用HepG2细胞进行的肝细胞增殖抑制试验结果表明,FD(SAC/βCD)抑制细胞增殖。另一方面,FD(SAC/αCD)和FD(SAC/γCD)未显示活细胞数量有显著减少。这些结果表明,包合模式的差异可能有助于稳定性和细胞增殖抑制。